Telis Bioscience

Telis Bioscience was a Cambridge, Massachusetts biotechnology company founded in 2019 to accelerate drug development through a platform that combined rapid protein synthesis, automated antibody screening, and deep learning-driven design. The company initially described itself as developing high-impact protein therapeutics, particularly antibody-based programs. In late 2021 to early 2022, Telis transitioned into or merged with Alvea, a pandemic-focused biotechnology company developing scalable, shelf-stable DNA vaccines, including an Omicron-targeted COVID-19 vaccine candidate. Alvea reported reaching first-in-human testing in 196 days from founding and later announced a wind-down in October 2023. As a result, Telis is best understood as a predecessor entity whose assets, team, and mission were absorbed into Alvea rather than an independently operating company today.